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 Background: A 70-gene signature was previously shown to 
have prognostic value in patients with node-negative breast 
cancer. Our goal was to validate the signature in an indepen-
dent group of patients.  Methods: Patients (n = 307, with 137 
events after a median follow-up of 13.6 years) from fi ve Euro-
pean centers were divided into high- and low-risk groups 
based on the gene signature classifi cation and on clinical risk 
classifi cations. Patients were assigned to the gene signature 
low-risk group if their 5-year distant metastasis – free survival 
probability as estimated by the gene signature was greater 
than 90%. Patients were assigned to the clinicopathologic 
low-risk group if their 10-year survival probability, as esti-
mated by Adjuvant! software, was greater than 88% (for 
estrogen receptor [ER] – positive patients) or 92% (for ER-
negative patients). Hazard ratios (HRs) were estimated to 
compare time to distant metastases, disease-free survival, 
and overall survival in high- versus low-risk groups.  Results: 
The 70-gene signature outperformed the clinicopathologic 
risk assessment in predicting all endpoints. For time to dis-
tant metastases, the gene signature yielded HR = 2.32 (95% 
confi dence interval [CI] = 1.35 to 4.00) without adjustment 
for clinical risk and hazard ratios ranging from 2.13 to 2.15 
after adjustment for various estimates of clinical risk; clini-
copathologic risk using Adjuvant! software yielded an unad-
justed HR = 1.68 (95% CI = 0.92 to 3.07). For overall survival, 
the gene signature yielded an unadjusted HR = 2.79 (95% 
CI = 1.60 to 4.87) and adjusted hazard ratios ranging from 
2.63 to 2.89; clinicopathologic risk yielded an unadjusted 
HR = 1.67 (95% CI = 0.93 to 2.98). For patients in the gene 
signature high-risk group, 10-year overall survival was 0.69 
for patients in both the low – and high – clinical risk groups; 
for patients in the gene signature low-risk group, the 10-year 
survival rates were 0.88 and 0.89, respectively.  Conclusions: 
The 70-gene signature adds independent prognostic infor-
mation to clinicopathologic risk assessment for patients with 
early breast cancer.  [J Natl Cancer Inst 2006;98: 1183 – 92 ] 
 Microarray technology is revolutionizing our understanding 
of cancer biology through the simultaneous study of the expres-
sion of tens of thousands of genes, or even of the entire human 
genome. Differential gene expression or molecular profi ling has 
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the potential to substantially refi ne cancer prognosis, well beyond 
what is currently possible with the clinical and pathologic indica-
tors used thus far for this purpose. Several studies have recently 
used microarrays to classify breast tumors on the basis of their 
gene expression profi les  ( 1 – 7 ) . These studies have consistently 
revealed considerable molecular diversity in breast cancer that 
often corresponds to distinct clinical phenotypes. Two major 
types, basal and luminal, have been identifi ed by gene expression 
profi ling of breast cancer, each with the potential to be subdi-
vided into two or three subtypes. In addition, these molecular 
portraits seem to be remarkably stable as tumors progress from 
primary to metastatic disease  ( 8 ) . 
 In one of the microarray studies  ( 5 ) , investigators from the 
Netherlands Cancer Institute in Amsterdam (NKI) studied a nar-
rowly defi ned subset of breast cancer patients, i.e., those aged 
55 years or younger who were diagnosed with tumors smaller 
than 5 cm (T1/T2), had no nodal involvement (N0) or metastases 
(M0), and were treated only with local – regional therapies. The 
ex pression of 231 genes was found to be statistically signifi cantly 
associated with disease outcome, as defi ned by the presence 
of distant metastasis within 5 years. This group of genes was 
 reduced subsequently to a core set of 70 genes that together 
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 constituted a signature of substantial prognostic ability. The investi-
gators also tested whether the 70-gene signature could identify 
patients who would need adjuvant chemotherapy and compared 
this prognostication with that of the widely accepted National 
 Institutes of Health and St Gallen guidelines for treatment of node-
negative breast cancer  ( 9 , 10 ) . The 70-gene signature correctly 
identifi ed not only the patients who needed adjuvant  chemotherapy 
but also those who did not need adjuvant chemotherapy, leading 
to a 20% – 30% reduction in the number of women who would 
otherwise receive chemotherapy without compromising long-term 
clinical outcome. The 70-gene signature was then applied to a 
larger test set of 295 breast cancer patients from the same institu-
tion, and the results confi rmed that the signature could clearly dis-
tinguish patients according to their 10-year survival outcome  ( 6 ) . 
 Since the publication of these results, a number of authors 
have highlighted critical issues in the use of microarray data for 
prognostic classifi cation, including gene selection bias, error 
 estimation, fragility of gene signatures, and overoptimistic per-
formance estimation due to model overfi t  ( 11 – 13 ) . Moreover, as 
promising as gene signatures are, it still needs to be proven that 
they provide additional information to the clinicopathologic risk 
criteria that are currently used in the clinic. Some authors have 
expressed doubts that they will add further prognostic value to 
that provided by the best risk classifi cations based on factors 
such as age, tumor size, tumor grade, nodal involvement, and 
presence of hormonal receptors  ( 9 , 10 , 14 – 17 ) . 
 If the clinical utility of gene signatures can be established — that 
is, if they prove to reliably identify patients in whom adjuvant 
chemotherapy is defi nitely not indicated despite having poor clin -
ical risk factors and patients who need chemotherapy despite 
 having good clinical risk factors — they will have enormous poten-
tial for better individualization of treatment options in breast can-
cer therapy  ( 18 ) . This potential — and the use of gene signatures in 
prognostication — requires that the recently proposed gene signatures 
be validated independently, preferably by teams external to the 
original institutions, using prospectively defi ned criteria. In this 
paper, we describe the results of a multinational collaborative ini-
tiative conducted under the aegis of the TRANSBIG consortium 
aimed at validating the 70-gene signature in breast cancer. 
 S UBJECTS  AND M ETHODS 
 Patients 
 This validation study was carried out with tumor samples and 
clinical data from patients seen at fi ve European centers: Institut 
Gustave Roussy, Villejuif, France; Karolinska Institute, Stockholm, 
Sweden; Centre René Huguenin, Saint-Cloud, France; Guy’s 
Hospital, London, U.K.; and John Radcliffe Hospital, Oxford, 
U.K. Patients were eligible for inclusion if they were younger 
than 61 years old at diagnosis, diagnosed before 1999 with node-
negative, T1 – T2 ( ≤ 5 cm) breast cancer, and had not  received 
 adjuvant systemic therapy. Patients with previous malignancies 
(except basal cell carcinoma) or with bilateral synchronous breast 
tumors were excluded. A total of 326 patients were included in 
what is hereafter referred to as the  “ validation ” series. Patients in 
this series had been diagnosed between 1980 and 1998 and had a 
median follow-up of 13.6 years. Data were also available for the 
151 node-negative patients included in the analyses carried out at 
the NKI to validate the 70-gene signature, hereafter referred to as 
the  “ original ” series  ( 6 ) . The validation protocol was fi nalized in 
July 2004. All institutional ethics committees approved the use of 
the tumor material for the purposes described in this article, and 
patients provided written informed consent. 
 Tumor Samples and Data Analysis 
 Initially, frozen samples from eligible patients (n = 403) were 
sent from all clinical centers to NKI for RNA extraction and mi-
croarray analysis, as pre viously described  ( 5 ) . Useful RNA could 
be extracted for hybridi zation and analysis from 81% of these fro-
zen samples, leaving 326 samples available for analysis. Paraffi n-
embedded tumor samples from all patients in both the original and 
the validation series were sent to the Department of Pathology 
at the European Institute of Oncology, Milan, where the same 
pathologist (GV) determined estrogen receptor (ER) status  [using 
immunohistochemistry  ( 19 ) ] and histologic grade [using the Elston 
and Ellis method  ( 20 ) ]. Whenever possible, these central pathol-
ogy data were used to determine ER status (n = 218) and histologic 
grade (n = 237); otherwise the local pathology data obtained at the 
original clinical center were used. Clinical centers were visited by 
two independent auditors who carried out source data verifi cation 
of all data in the validation series. Clinical, pathologic, and gene 
signature data were centralized at the TRANSBIG Secretariat at 
Institut Jules Bordet. Statistical ana lyses were carried out by the 
International Drug Development Institute, Brussels, Belgium. 
 Gene Signature Risk Classifi cation 
 Microarray analysis was performed at Agendia Laboratories, 
a spinoff company of the NKI, using a custom-designed array 
chip known as Mammaprint. This array chip assesses the mRNA 
expression of the 70 genes in triplicate and was manufactured by 
Agilent Technologies using the Agilent oligonucleotide micro-
array platform. A tumor was defi ned as having a low-risk gene sig -
nature if the Pearson correlation coeffi cient for the expression of 
the 70-gene profi le in that tumor with the previously established 
classifi er was above 0.4, the cut point used in the original study 
 ( 5 ) . The previously established classifi er defi ned good prognosis 
as a probability of 5-year distant metastasis – free survival of more 
than 90%  ( 5 ) . The gene signature risk classifi cation was given as 
a dichotomized value only: high or low risk. Raw microarray 
data and clinical information are available at the European Bio -
in formatics Institute ArrayExpress database ( http://www.ebi.ac.
uk/arrayexpress/ ), accession number E-TABM-77. Normalized 
microarray data were archived by the Swiss Institute of Bioinfor-
matics, where a study statistician (MD) reviewed and indepen-
dently applied Agendia’s proprietary analysis program to the 
normalized microarray raw data to reproduce the risk classifi ca-
tion. The risk classifi cation agreement between Swiss Institute of 
Bioinformatics and Agendia was assessed by independent study 
statisticians (MB, MA, FP). The concordance between the risk 
classifi cation produced by Agendia and the external team was 
100% as verifi ed by the independent statisticians. 
 Clinical Risk Classifi cation 
 The aim of this validation study was to examine whether the 
70-gene signature had prognostic value independent of the best 
clinical risk classifi cations. The prognostic value of the gene sig-
nature was fi rst assessed with respect to the St Gallen criteria  ( 9 ) 
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and the Nottingham Prognostic Index (NPI)  ( 15 ) . Patients with 
an NPI score of less than or equal to 3.4, the standard NPI cut 
point, were classifi ed as low risk. However, the St Gallen criteria 
classifi ed very few patients as low risk, and the NPI takes neither 
the patient’s age nor the ER status of her tumor into account. The 
prognostic value of the gene signature was, therefore, also as-
sessed using the recently introduced Adjuvant! software [ http://
www.adjuvantonline.com  ( 16 ) ], which calculates 10-year sur-
vival probability based on the patient’s age, tumor size and grade, 
tumor ER status, and nodal status (which was negative for all 
patients in this study). In a recent external validation, Adjuvant! 
software was shown to accurately predict overall survival, breast 
cancer – specifi c survival, and event-free survival in 4083 women 
diagnosed with early breast cancer in British Columbia between 
1989 and 1993  ( 21 ) . 
 Although it is possible to use the outcomes produced by Adju-
vant! software as a continuous variable, clinical decision making 
assumes a dichotomization into a low- and a high-risk group. It 
was decided by consensus among the TRANSBIG Consortium 
members (see  http://www.breastinternationalgroup.org ) that the 
low – clinical risk group would be defi ned as patients with 10-year 
overall survival probabilities (as calculated by Adjuvant! soft-
ware, version 7.0) of at least 88% if 10% or more of the tumor 
cells expressed detectable ER (i.e., ER-positive tumors) and of 
at least 92% if ER expression was seen in less than 10% of the 
tumor cells (i.e., ER-negative tumors). These two cutoffs were 
chosen to refl ect the fact that patients with ER-positive tumors 
routinely receive adjuvant endocrine therapy [with an estimated 
absolute 10-year survival benefi t of approximately 4% overall 
 ( 22 ) ], although none of the patients in the validation series re-
ceived adjuvant endocrine therapy, regardless of their ER status. 
However, to rule out the possibility that our results were depen-
dent on the choice of clinical cutoff, we carried out a sensitivity 
analysis in which we varied the 10-year overall survival proba-
bility cutoff that defi ned low risk, as predicted by Adjuvant! soft-
ware, from 60% (in which case most patients were classifi ed in 
the low – clinical risk group) to 95% (in which case most patients 
were classifi ed in the high – clinical risk group), without distinc-
tion between ER-positive and -negative patients. 
 Endpoints 
 We analyzed three main endpoints: time from surgery to dis-
tant metastases, which was the endpoint used to identify the gene 
signature  ( 5 ) (all other events were ignored for this endpoint); 
overall survival, which was defi ned as time from surgery to death 
from any cause; and disease-free survival, which was defi ned as 
time from surgery to any recurrence (local or regional), second 
breast primary, distant metastasis, or death from any cause. The 
Kaplan – Meier product-limit estimator was used to display time-
to-event curves for these three endpoints. 
 Validation Strategy 
 Validation of the gene signature was based on the estimation 
of hazard ratios, which were used to quantify the relative risk of 
an event in the high-risk group compared with the low-risk group. 
A hazard ratio above 1.0 indicates that patients in the high-risk 
group have a higher probability of an event (distant metastasis, 
death from any cause, or recurrence or death) than patients in the 
low-risk group for the outcomes considered (time to distant 
 metastasis, overall survival, and disease-free survival, respec-
tively). Hazard ratios were stratifi ed by clinical center to account 
for  possible heterogeneity in patient selection or other potential 
 confounders among the various centers. Hazard ratios for the risk 
groups defi ned by the gene signature were estimated with strati-
fi cation for clinical risk to refl ect the prognostic impact of the 
gene signature over and above that of clinicopathologic factors 
(adjusted hazard ratios). 
 The adjusted hazard ratios (with their 95% confi dence inter-
vals [CIs]) for the fi ve institutions that supplied patients for this 
study were displayed on forest plots and tested for heterogeneity 
using a chi-square test with four degrees of freedom. The impact 
of the duration of follow-up on the adjusted hazard ratios was 
analyzed by censoring all observations at increasing time points. 
 We estimated that approximately 100 patients with a cancer-
related event would be needed for the validation to yield results 
with both clinical relevance (i.e., doubling of the risk of an event) 
and statistical signifi cance (i.e., a power of 90% to detect a haz-
ard ratio of 2.0 or greater at a statistical signifi cance level of .05). 
After a median follow-up of 13.6 years, a total of 137 patients in 
the validation series had at least one event. These events included 
68 recurrences, 31 second primary cancers, 77 distant metasta-
ses, and 82 deaths. 
 Sensitivity and Specifi city 
 Sensitivity and specifi city were estimated for both risk assess-
ments (i.e., the gene signature and clinicopathologic assessments) 
for distant metastases within 5 years (the endpoint used to derive 
the gene signature) and for death within 10 years (the endpoint 
used to defi ne the clinical cutoff when using Adjuvant! software). 
Sensitivity was defi ned as the probability that a patient who expe-
rienced the event of interest was in the high-risk group and speci-
fi city as the probability that a patient who did not experience the 
event of interest was in the low-risk group. Time-dependent re-
ceiver operating characteristic (ROC) curves  ( 23 ) were computed 
by using the tumor expression level for the gene signature  ( 5 ) and 
the 10-year survival probability for the Adjuvant! software  ( 17 ) . 
 R ESULTS 
 Patients Included in the Analyses 
 Data on tumor size were missing for three of the 326 patients 
in the validation series, and 16 patients were found to be ineligible 
in the independent data verifi cation (for 10 patients, only comedo-
carcinoma or ductal carcinoma in situ was detected at central 
 pathology review; two patients had metastatic disease at the time 
of diagnosis; one patient had a bilateral breast cancer; one patient 
had a previous malignancy; one patient was older than 61 years; 
and one patient had a tumor that was larger than 5 cm). Of the 
remaining 307 patients, data on ER status were missing for fi ve 
patients. All analyses were repeated with the inclusion of the in-
eligible patients, and the results were similar (data not shown). 
 Patient Characteristics 
 The 70-gene signature risk classifi cation was assessed for 
each tumor, and tumors were scored as low or high risk according 
to the previously established classifi er  ( 5 ) .  Table 1 shows the 
characteristics of the 302 patients of the validation series for 
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whom clinical risk could be calculated using the Adjuvant! soft-
ware (i.e., the patients for whom data on ER status were avail-
able). The patients were divided into four groups according to 
their clinical and gene signature risks. Analysis of 10-year sur-
vival data ( Table 1 ) showed that, for patients in the gene signature 
high-risk category, the 10-year overall survival was 0.69 for 
 patients in both low – and high – clinical risk groups, whereas for 
patients in the gene signature low-risk category, the 10-year 
 survivals were 0.88 and 0.89, respectively. The Kaplan – Meier 
estimates of time to distant metastases, overall survival, and disease-
free survival for the four groups of patients ( Fig. 1 ) suggest that, 
for groups with discordant risk assessments (i.e., high risk ac-
cording to one risk classifi er and low risk according to the other), 
the gene signature provided stronger prognostic information than 
the clinicopathologic criteria. 
 Unadjusted and Adjusted Hazard Ratios 
 The unadjusted hazard ratios for the three outcomes in high- 
versus low-risk patients as defi ned by traditional individual clini-
copathologic factors and by various risk classifi cations are shown 
in  Table 2 . The prognostic value of the gene signature was stron-
ger than that of the individual traditional risk factors and of the 
commonly used clinicopathologic risk classifi cations. The unad-
justed gene signature hazard ratio for time to distant metastases 
was 2.32 (95% CI = 1.35 to 4.00), higher than that for any of the 
other risk factors or classifi cations. Adjustment of the gene signa-
ture hazard ratio for the St Gallen criteria, for the NPI, and for 
the clinical risk groups based on 10-year survival probability as 
calculated by Adjuvant! software resulted in gene signature 
 hazard ratios of 2.15 (95% CI = 1.25 to 3.71), 2.15 (95% CI = 
1.19 to 3.92), and 2.13 (95% CI = 1.19 to 3.82), respectively. 
The gene signature hazard ratio for overall survival was 2.79 
(95% CI = 1.60 to 4.87) without adjustment and 2.69 (95% CI = 
1.53 to 4.73), 2.89 (95% CI = 1.58 to 5.29), and 2.63 (95% CI = 
1.45 to 4.79) with the respective adjustments. The gene signature 
hazard ratio for disease-free survival was 1.50 (95% CI = 1.04 
to 2.16) without adjustment and 1.41 (95% CI = 0.97 to 2.06), 
1.45 (95% CI = 0.97 to 2.16), and 1.36 (95% CI = 0.91 to 2.03) 
with the respective adjustments. 
 The reverse analysis was also performed, i.e., the hazard ra-
tios for the clinical risk classifi cations were adjusted for the gene 
signature. For the risk classifi cation according to the Adjuvant! 
software, the unadjusted hazard ratio for time to distant metas-
tases was 1.68 (95% CI = 0.92 to 3.07) without adjustment and 
1.26 (95% CI = 0.66 to 2.40) when adjusted for the gene signa-
ture; for overall survival, the hazard ratios were 1.67 (95% CI = 
0.93 to 2.98) without adjustment and 1.08 (95% CI = 0.59 to 
1.99) with adjustment; and for disease-free survival, the hazard 
ratios were 1.30 (95% CI = 0.86 to 1.95) without adjustment and 
1.03 (95% CI = 0.67 to 1.59) with adjustment. 
 Heterogeneity Among Centers and Between Patient Series 
 Forest plots of the gene signature hazard ratios for each 
 center, adjusted for the clinical risk groups as defi ned by the 
Adjuvant! software ( Fig. 2, A – C ), indicated that there was no 
statistically signifi cant heterogeneity among the fi ve centers 
from which the validation series was drawn for any of the end-
points considered. However, statistically signifi cant heteroge-
neity was apparent between the validation series and the original 
series, with the latter series showing much larger hazard ratios 
for all endpoints considered. By contrast, forest plots of the 
Adjuvant! software clinical risk  hazard ratios , adjusted for the 
gene signature ( Fig. 2, D – F ), revealed no statistically signifi -
cant heterogeneity among the different centers of the validation 
series or between the validation series and the original series 
for any of the endpoints. 
 Impact of Clinical Risk Cutoff 
 In a sensitivity analysis, we varied the cutoffs that defi ned low 
risk in the Adjuvant! software and used the resulting clinical risk 
groups to adjust the gene signature hazard ratios ( Fig. 3 ). The 
adjusted gene signature hazard ratios were statistically  signifi cant 
 Table 1.  Characteristics of patients in the validation series according to their clinical and gene signature risks * 
 Clinical low risk  Clinical high risk
Characteristic
Gene signature 
low risk (n = 52)
Gene signature 
high risk (n = 28)
Gene signature 
low risk (n = 59)
Gene signature 
high risk (n = 163)
Age, y
  <41 8 1 9 40
  41 – 50 36 22 20 67
  51 – 60 8 5 30 56
Tumor size
  T1ab (<1 cm) 5 4 0 2
  T1c (1 – 2 cm) 30 12 17 40
  T2 (2 – 5 cm) 17 12 42 121
Tumor grade
  Good differentiation 22 12 7 6
  Intermediate differentiation 29 16 41 39
  Poor differentiation 0 0 11 113
  Unknown 1 0 0 5
Estrogen receptor status
  Positive 52 28 54 78
  Negative 0 0 5 85
Proportion alive at 10 y 
  (95% confi dence intervals)
0.88 (0.74 to 0.95) 0.69 (0.45 to 0.84) 0.89 (0.77 to 0.95) 0.69 (0.61 to 0.76)
 * Although the validation series included 307 patients, those whose clinical risk could not be calculated due to missing values for any of the variables were 
excluded (n = 5). 
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( P values not shown), regardless of the cutoff chosen, for both 
time to distant metastases and overall survival. However, for 
 disease-free survival most, but not all, cutoffs achieved only bor-
derline statistical signifi cance. 
 Impact of Follow-up Duration 
 The analyses reported above were carried out without arbi-
trary censoring of observations. However, because the median 
follow-up time in the original series was less than half that of the 
validation series (6.7 years versus 13.6 years, respectively), we 
also calculated the gene signature hazard ratios adjusted for clin-
ical risk groups as defi ned by Adjuvant! software with arbitrary 
censoring of all observations at increasing time points. As shown 
in  Fig. 4 , the adjusted gene signature had the greatest prognostic 
value (as shown by the highest hazard ratio) at identifying pa-
tients at high risk of an event within 5 years. These analyses sug-
gest that the different duration of follow-up may explain some of 
the discrepancy in hazard ratios reported between the original 
series and the current validation series. 
 Sensitivity and Specifi city 
 Time-dependent ROC curves ( Fig. 5 ) showed that the predic-
tive accuracy of the gene signature was as least as good as that of 
Adjuvant! software, with a high sensitivity (i.e., a low probability 
of falsely classifying a patient as low risk). The sensitivities for 
distant metastases within 5 years and for death within 10 years 
were similar for the gene signature and for the various clinico-
pathologic risk assessments ( Table 3 ). The specifi city, however, 
was higher for the gene signature than for Adjuvant!. Among the 
215 patients with a concordant risk classifi cation by the Adju-
vant! software and the gene signature, the sensitivity of the Adju-
vant! software was slightly higher than that of the gene signature 
and the specifi city was slightly lower. In contrast, among the 87 
patients with a discordant gene signature and Adjuvant! risk clas-
sifi cation, the sensitivity of the Adjuvant! software was very poor, 
as was also suggested by the Kaplan – Meier analyses ( Fig. 1 ). 
 D ISCUSSION 
 Our analyses confi rm that the 70-gene signature  ( 5 ) is a strong 
prognostic factor for time to distant metastases and overall sur-
vival in untreated patients with node-negative breast cancer, with 
unadjusted hazard ratios of 2.32 (95% CI = 1.35 to 4.00) and 2.79 
(95% CI = 1.60 to 4.87), respectively. The signature remained 
a statistically signifi cant prognostic factor for time to distant 
metastases and survival even after adjustment for various risk 
classifi cations that take into account all clinicopathologic fac-
tors known to have prognostic value in this disease. In particular, 
when adjusted for the clinical risk groups based on 10-year sur-
vival probability as calculated by the Adjuvant! software, the 
gene signature hazard ratios were 2.13 (95% CI = 1.19 to 3.82) 
for time to distant metastases, 2.63 (95% CI = 1.45 to 4.79) for 
overall survival, and 1.36 (95% CI = 0.91 to 2.03) for disease-
free survival ( Fig. 2 ). (The lack of statistical signifi cance for 
 disease-free survival is not surprising because the signature was 
developed using only time to distant metastases as an endpoint.) 
These results indicate that the gene signature adds independent 
prognostic information to that provided by a risk assessment 
based solely on clinicopathologic factors. 
 Fig. 1.  Kaplan – Meier curves by clinical and gene signature risk groups.  A ) Time 
to distant metastases.  B ) Overall survival.  C ) Disease-free survival.  Error bars 
show 95% confi dence intervals. 
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 Table 2.  Hazard ratios (with 95% confi dence intervals) and  P values for individual risk factors and risk classifi cations 
Risk factor or classifi cation Time to distant metastases Overall survival * Disease-free survival † 
Age ( ≤ 50y versus >50y) 0.86 (0.54 to 1.37) 0.84 (0.54 to 1.32) 1.17 (0.82 to 1.68)
 P = .52  P = .46  P = .40
Tumor size (T2 versus T1) 1.42 (0.90 to 2.23) 1.36 (0.87 to 2.12) 1.20 (0.85 to 1.68)
 P = .14  P = .18  P = .31
Tumor grade (good versus intermediate versus 
 poor differentiation)
0.76 (0.54 to 1.07)
 P = .12
0.82 (0.60 to 1.14)
 P = .25
0.96 (0.75 to 1.22)
 P = .72
Estrogen receptor status (negative versus positive) 2.18 (1.37 to 3.48) 2.36 (1.50 to 3.72) 1.49 (1.03 to 2.14)
 P = .001  P <.001  P = .033
Adjuvant! software (high risk versus low risk) 1.68 (0.92 to 3.07) 1.67 (0.93 to 2.98) 1.30 (0.86 to 1.95)
 P = .092  P = .085  P = .21
Nottingham Prognostic Index 
 (high risk versus low risk) ‡ 
1.65 (1.02 to 2.66)
 P = .043
1.49 (0.94 to 2.36)
 P = .092
1.10 (0.78 to 1.56)
 P = .58
St Gallen criteria (high risk versus low risk) § 2.22 (0.70 to 7.08) 1.69 (0.62 to 4.66) 2.18 (0.96 to 4.96)
 P = .18  P = .31  P = .064
Gene signature (high risk versus low risk) || 2.32 (1.35 to 4.00) 2.79 (1.60 to 4.87) 1.50 (1.04 to 2.16)
 P = .002  P <.001  P = .032
 * For overall survival, the event considered was death from any cause. Hazard ratios above 1.0 indicate a worse outcome. 
 † For disease-free survival, the event considered was death or recurrence. Hazard ratios above 1.0 indicate a worse outcome . 
 ‡ ( 15 ) . 
 § ( 9 ). 
 || ( 5 ). 
 Fig. 2.  Forest plots of hazard ratios (HRs) and 95% confi dence intervals 
(CIs) for each event in the high-risk versus low-risk groups for the gene 
signature and clinical risk classifi ers. ( A – C ) Hazard ratios for the gene signature 
classifi cation, adjusted for clinical risk based on the 10-year survival probability 
as calcu lated by Adjuvant! software. ( D – F ) Hazard ratios for the Adjuvant! 
software classifi cation, adjusted for the gene signature risk. ( A and  D ) Time to 
distant metastases. ( B and  E ) Overall survival. ( C and  F ) Disease-free survival. 
Numbers of events and patients in each risk group are indicated. IGR = Institut 
Gustave Roussy; KI = Karolinska Institute; CRH = Centre René Huguenin; 
GH = Guy’s Hospital; JRH = John Radcliffe; NKI = Netherlands Cancer Institute; 
 squares = HRs;  lines = 95% CIs;  diamond = HR and 95% CI for all fi ve 
institutions in the validation series (IGR, KI, CRH, GH, and JRH) combined. 
 Size of squares is inversely proportional to the variance of the hazard ratio in 
each center. 
1.00.2 10
Low High Adjusted High risk    Low risk
Center Events/Patients Events/Patients HR (CI) better    better
IGR 7 / 46 15 / 50 2.06(0.81,5.25)
KI 2 / 27 10 / 33 9.93(1.13,87.27)
CRH 4 / 17 8 / 38 1.11(0.31,3.99)
GH 5 / 16 18 / 37 1.64(0.57,4.71)
JRH 0 / 5 7 / 33 >100 (-,-)
All 5 18 / 111 58 / 191 2.13(1.19,3.82)
NKI 7 / 60 47 / 91 6.07(2.64,13.98)
A
1.00.2 10
Low High Adjusted High risk    Low risk
Center Events/Patients Events/Patients HR (CI) better    better
IGR 5 / 29 17 / 67 1.11(0.39,3.12)
KI 3 / 20 9 / 40 0.97(0.19,4.86)
CRH 1 / 10 11 / 45 1.77(0.22,14.02)
GH 3 / 10 20 / 43 1.41(0.39,5.13)
JRH 1 / 11 6 / 27 1.53(0.18,12.78)
All 5 13 / 80 63 / 222 1.26(0.66,2.40)
NKI 11 / 42 43 / 109 1.02(0.51,2.03)
D
1.00.2 10
Low High Adjusted High risk    Low risk
Center Events/Patients Events/Patients HR (CI) better    better
IGR 4 / 46 14 / 50 3.42(1.05,11.14)
KI 2 / 27 13 / 33 8.93(1.78,44.87)
CRH 4 / 17 8 / 38 1.02(0.30,3.48)
GH 6 / 16 21 / 37 1.74(0.65,4.63)
JRH 0 / 5 9 / 33 >100 (-,-)
All 5 16 / 111 65 / 191 2.63(1.45,4.79)
NKI 2 / 60 41 / 91 17.46(4.12,74.00)
B
1.00.2 10
Low High Adjusted High risk    Low risk
Center Events/Patients Events/Patients HR (CI) better    better
IGR 4 / 29 14 / 67 0.94(0.29,3.01)
KI 4 / 20 11 / 40 0.59(0.17,2.00)
CRH 1 / 10 11 / 45 2.54(0.32,20.26)
GH 4 / 10 23 / 43 1.15(0.36,3.65)
JRH 1 / 11 8 / 27 1.78(0.22,14.34)
All 5 14 / 80 67 / 222 1.08(0.59,1.99)
NKI 7 / 42 36 / 109 1.08(0.47,2.46)
E
1.00.2 10
Low High Adjusted High risk    Low risk
Center Events/Patients Events/Patients HR (CI) better    better
IGR 17 / 46 23 / 50 1.26(0.66,2.43)
KI 7 / 27 16 / 33 2.67(0.93,7.71)
CRH 10 / 17 12 / 38 0.51(0.21,1.25)
GH 9 / 16 26 / 37 1.80(0.79,4.15)
JRH 1 / 5 16 / 33 2.64(0.30,23.28)
All 5 44 / 111 93 / 191 1.36(0.91,2.03)
NKI 10 / 60 55 / 91 4.80(2.37,9.71)
C
1.00.2 10
Low High Adjusted High risk    Low risk
Center Events/Patients Events/Patients HR (CI) better    better
IGR 9 / 29 31 / 67 1.30(0.60,2.82)
KI 7 / 20 16 / 40 0.72(0.26,2.00)
CRH 5 / 10 17 / 45 0.97(0.32,2.97)
GH 6 / 10 29 / 43 1.06(0.41,2.79)
JRH 4 / 11 13 / 27 0.94(0.30,2.96)
All 5 31 / 80 106 / 222 1.03(0.67,1.59)
NKI 12 / 42 53 / 109 1.28(0.67,2.45)
F
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 Interestingly, when the reverse analysis was performed, i.e., 
when clinical risk hazard ratios were adjusted for the gene sig-
nature, none of the clinical risk classifi cations retained statistical 
signifi cance ( Fig. 2 ). This fi nding suggests that most of the in-
formation provided by risk groups based on clinicopathologic 
 factors is subsumed by the gene signature. The Kaplan – Meier 
curves ( Fig. 1 ) provide additional evidence for this conclusion in 
that within each gene signature risk group the curves for low – 
versus high – clinical risk groups were close to each other. For 
patients in the gene signature high-risk group, the point estimate 
of 10-year survival was 0.69 in both the low – and high – clinical 
risk groups, and for patients in the gene signature low-risk group, 
the point estimates of 10-year survival were 0.88 and 0.89, re-
spectively ( Table 1 ), thus demonstrating the higher discrimina-
tory prognostic ability of the gene signature. 
 We also found that the prognostic value of the gene signature 
was almost completely independent of the defi nition of clinical 
risk. That is, a series of adjustments for clinical risk using vary-
ing cutoff points in the Adjuvant! software produced only minor 
changes in the gene signature hazard ratios ( Fig. 3 ). The approach 
used in our analyses — i.e., estimating adjusted hazard ratios 
through stratifi cation — is preferable to a multivariable analysis 
because it does not require any assumption of proportional haz-
ards for either the gene signature or the clinicopathologic factors. 
Moreover, it is less sensitive to random fl uctuations in the data 
 Fig. 3.  Hazard ratios (and 95% confi dence intervals) for gene signature high-risk 
versus low-risk groups, adjusted for the clinical risk groups based on 10-year 
survival probability as calculated by Adjuvant! software. The x-axis indicates 
the cutoff points of the 10-year survival probabilities used to defi ne high clinical 
risk in the adjustment.  A ) Time to distant metastases;  B ) overall survival; and 
C ) disease-free survival.  Diamonds , hazard ratios;  vertical lines , 95% confi dence 
intervals;  shaded bars , proportion of patients in each high – clinical risk group as 
defi ned by each cutoff for 10-year survival. 
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 Fig. 4.  Hazard ratios (and 95% confi dence intervals) for gene signature high-
risk versus low-risk groups, adjusted for clinical risk groups based on 10-year 
survival probability as calculated by Adjuvant! software, for increasing arbitrary 
censoring times. The x-axis indicates the time at which all observations were 
censored.  A ) Time to distant metastases;  B ) overall survival; and  C ) disease-
free survival.  Diamonds , hazard ratios;  vertical lines , 95% confi dence intervals; 
 shaded bars , proportion of patients in each time point. It should be noted that 
when the data were censored at 2 years, all eight events were in the high-risk 
group and no hazard ratio could be estimated. 
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and multicolinearity between the variables, which may lead to 
model instability in multivariable analysis  ( 24 ) . 
 There was no evidence of heterogeneity among the various 
centers participating in the validation study for any of the endpoints 
( Fig. 2 ). In contrast, there was striking evidence of heterogeneity 
between the validation and the original series  ( 6 ) : the hazard 
 ratios in the original series were much higher than those in 
the validation series for risk classifi cations based on either the 
clinicopathologic factors or the gene signature. The gene  signature 
hazard ratio also remained much higher after adjustment in the 
original series  ( 6 ) than in the current validation series. It has pre-
viously been noted  ( 12 ) that the inclusion in the original series of 
patients whose data were used in the development of the 70-gene 
signature may have infl ated the discriminatory power of the sig-
nature in that study, even though analytic measures had been 
 Fig. 5.  Receiver operating characteristic (ROC) curves of gene signature and of 
Adjuvant! software. ( top ) ROC curves for metastases within 5 years ( left ) and 
for death within 10 years ( right ) for gene signature, using the Agendia score 
(correlation of the gene signature with the previously established classifi er). 
( bottom ) ROC curves for metastases within 5 years ( left ) and for death within 
10 years ( right ) for Adjuvant! software, using the score generated by the 
Adjuvant! online software. AUC = area under the curve. 
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 Table 3.  Sensitivity and specifi city (with 95% confi dence intervals) of gene signature and of clinicopathologic risk assessments for metastases 
within 5 years and for death within 10 years * 
Risk classifi cation
 Number of patients 
in risk groups
 Metastases 
within 5 years
 Deaths 
within 10 years
High risk Low risk Sensitivity Specifi city Sensitivity Specifi city
Gene signature 194 113 0.90 (0.78 to 0.95) 0.42 (0.36 to 0.48) 0.84 (0.73 to 0.92) 0.42 (0.36 to 0.48)
Adjuvant! software 222 80 0.87 (0.75 to 0.94) 0.29 (0.24 to 0.35) 0.82 (0.71 to 0.90) 0.29 (0.23 to 0.35)
Nottingham Prognostic Index 169 130 0.79 (0.65 to 0.88) 0.48 (0.42 to 0.54) 0.70 (0.57 to 0.80) 0.47 (0.41 to 0.53)
St Gallen criteria 274 27 0.96 (0.86 to 0.99) 0.10 (0.07 to 0.14) 0.95 (0.86 to 0.98) 0.10 (0.07 to 0.14)
Adjuvant! software concordant 
 with gene signature
163 52 0.93 (0.81 to 0.98) 0.28 (0.22 to 0.35) 0.90 (0.78 to 0.95) 0.28 (0.22 to 0.35)
Adjuvant! software discordant 
 with gene signature
59 † 28 ‡ 0.40 (0.12 to 0.77) 0.30 (0.22 to 0.41) 0.44 (0.19 to 0.73) 0.29 (0.21 to 0.40)
 * Number of patients who could not be classifi ed because of missing clinical data was as follows: fi ve for the Adjuvant! software, eight for the Nottingham 
 Prognostic Index, and six for the St Gallen criteria. 
 †Clinical high risk, gene signature low risk.
 ‡ Clinical low risk, gene signature high risk. 
taken to limit this effect  ( 12 ) . It should also be noted that the only 
clinical factor that reached statistical signifi cance in the valida-
tion series was ER status, which suggests that the selection of 
patients who had not received systemic adjuvant treatment in the 
validation series may have yielded a sample of node-negative 
breast cancer patients with a relatively better outcome than what 
would be expected in a population-based series. All clinical data 
were carefully reviewed by independent site audits, so it is un-
likely that the quality of these data could have affected our results 
to an extent suffi cient to explain the differences between the re-
sults of the validation and original series. Likewise, it seems un-
likely that a problem with the quality of the pathologic data in the 
validation series could explain the differences with the original 
series. When the analysis was restricted to patients for whom 
both centrally and locally reviewed pathology data were avail-
able, the results were almost identical regardless of whether the 
central or local pathology data were used (data not shown). A 
plausible explanation for the observed discrepancy between the 
validation series and the original series is the difference in 
follow-up time [13.6 years for the validation series and 6.7 years 
for the original series  ( 6 ) ]. As  Fig. 4 shows, the behavior of the 
adjusted hazard ratio of the gene signature shows substantial 
variation over time, suggesting that the ability of the gene signa-
ture to identify those who will develop distant relapse is greatest 
within 5 years of diagnosis. 
 The differences in the results from the original and validation 
series, whatever their cause, underline the need to validate gene 
signatures on independent datasets from patients with suffi -
ciently long follow-up before they can be used routinely in the 
clinic for prognostic or predictive purposes. The very long 
 follow-up of patients in our validation series enabled us to dem-
onstrate that the risk classifi cation by gene signature provides 
additional independent prognostic information from that of clin-
icopathologic features ( Fig. 3 ) but is highly dependent on cen-
soring time ( Fig. 4 ). We also achieved our main objectives of 
the validation study, i.e., to determine whether the 70-gene sig-
nature had reproducible prognostic value across different patient 
populations, different laboratories, and different biostatistical 
facilities. 
 Although our results demonstrated that adjusted hazard ratios 
are a clinically useful measure to quantify the impact of the gene 
signature over and above that of clinicopathologic factors, 
 predictive accuracy is the more relevant measure to use when 
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comparing the prognostic performances of different risk classifi -
cations  ( 24 , 25 ) . In the validation series, the areas under the ROC 
curves were slightly higher for the gene signature classifi cation 
than for the Adjuvant! software classifi cation ( Fig. 5 ). All risk 
classifi cations for patients with early breast cancer attempt to 
identify reliably patients at low risk of metastasis or death, i.e., to 
achieve high sensitivity, even if this comes at the cost of very low 
specifi city. In this respect, the gene signature performed better 
than any of the classifi cations based on clinicopathologic factors 
 ( Table 3 ). The sensitivity of the Adjuvant! software classifi cation 
was somewhat improved when the gene signature was used to 
identify patients with concordant risks (low or high) by both clas-
sifi cation systems. By contrast, the sensitivity of Adjuvant! soft-
ware was very poor for patients with discordant risks by both 
classifi cation systems. 
 Many clinicians and scientists have expressed concerns about 
the lack of overlap among the genes included in different prog-
nostic gene signatures  ( 13 , 26 ) . The reason for the selection of 
different genes to predict the same outcome has been attributed 
to differences among microarray platforms, to differences among 
genes used in the array, to differences among experimental con-
ditions, and to chance. Another prognostic signature for node-
negative breast cancer has recently been developed using 
Affymetrix technology  ( 7 ) and validated using independent data 
from four European centers  ( 27 ) . Although the Agilent-based and 
Affymetrix-based gene expression signatures have only three 
genes in common, it is possible that other genes included in these 
prognostic signatures may be involved in the same underlying 
biologic processes, and both gene signatures may be equally use-
ful as prognostic tools  ( 28 ) . The TRANSBIG consortium is cur-
rently evaluating the performance of the Affymetrix-based gene 
expression signature using the same methodology and patient 
series as described here. 
 The present validation study used retrospective data from pa-
tients who had not received systemic adjuvant therapy, who may 
not be completely representative of today’s node-negative early-
stage breast cancer population. Nevertheless, we believe that 
the results justify proceeding to a prospective study. The goal of 
our study was to verify the independent prognostic value of 
the previously reported 70-gene signature in a population in 
which the results could not be confounded by treatment effects. 
Although most breast cancer patients currently receive endocrine 
treatment — e.g., women with ER-positive tumors currently 
 receive tamoxifen — in the future they might receive another 
 en docrine therapy (an aromatase inhibitor, for example), and the 
gene signature would still be applicable in identifying women 
with a poor clinical outcome. The large collaborative MINDACT 
(Microarray In Node-negative Disease may Avoid Chemotherapy 
Trial) conducted by the Breast International Group and coor-
dinated by the European Organisation for the Research and 
 Treatment of Cancer Breast Cancer Group will recruit 6000 
women with node-negative early-stage breast cancer to investi-
gate the benefi t-to-risk ratio of chemotherapy when the risk 
 assessment based on clinicopathologic factors  differs from that 
provided by the gene signature ( Fig. 6 )  ( 29 ) . In particular, the 
focus will be on the groups of women who are discordant by the 
risk classifi cations to compare the clinical value of the gene sig-
nature with that of the Adjuvant! software. This discordant group 
will be randomly assigned to have their treatment (i.e., adjuvant 
chemotherapy) decision making dependent on either the gene 
signature or Adjuvant! software. We hypothesize that the low-
risk group (as defi ned by the gene signature) will have an excel-
lent distant metastases – free survival at 5 years without adjuvant 
chemotherapy, thus sparing a substantial proportion of women 
who previously would have received adjuvant chemotherapy 
(because they were deemed at high risk for relapse by Adjuvant! 
software) unnecessary toxicity. The trial will provide level-1 evi-
dence about the clinical relevance of the 70-gene signature. 
Moreover, because biologic material (including frozen tumor 
samples) will be collected from all patients, this trial will have 
great potential for the identifi cation and validation of additional 
gene signatures with better prognostic and predictive value in 
early breast cancer. 
 REFERENCES 
  (1)  West M, Blanchette C, Dressman H, Huang E, Ishida S, Spang R, et al. Pre-
dicting the clinical status of human breast cancer by using gene expression 
profi les.  Proc Natl Acad Sci U S A  2001 ; 98 : 11462 – 7. 
  (2)  Sotiriou C, Neo SY, McShane LM, Korn EL, Long PM, Jazaeri A, et al. 
Breast cancer classifi cation and prognosis based on gene expression pro -
fi les from a population-based study.  Proc Natl Acad Sci U S A  2003 ; 100 : 
10393 – 8. 
  (3)  Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al. Gene 
expression patterns of breast carcinomas distinguish tumour subclasses with 
clinical implications.  Proc Natl Acad Sci U S A  2001 ; 98 : 10869 – 74. 
  (4)  Huang E, Cheng SH, Dressman H, Pittman J, Tsou MH, Horng CF, et al. Gene 
expression predictors of breast cancer outcomes.  Lancet  2003 ; 361 : 1590 – 6. 
  (5)  van’t Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, et al. 
Gene expression profi ling predicts clinical outcome of breast cancer.  Nature 
 2002 ; 415 : 530 – 6. 
  (6)  van de Vijver MJ, He YD, van’t Veer LJ, Dai H, Hart AA, Voskuil DW, 
et al. A gene-expression signature as a predictor of survival in breast cancer. 
 N Engl J Med  2002 ; 347 : 1999 – 2009. 
  (7)  Wang Y, Klijn J, Zhang Y, Sieuwerts A, Look MP, Atkins D, et al. Gene-
expression profi les to predict distant metastasis of lymph-node-negative 
primary breast cancer.  Lancet  2005 ; 365 : 671 – 9. 
  (8)  Weigelt B, Glas AM, Wessels LF, Witteveen AT, Peterse JL, van’t Veer LJ. 
Gene expression profi les of primary breast tumors maintained in distant 
metastases.  Proc Natl Acad Sci U S A  2003 ; 100 : 15901 – 5. 
  (9)  Goldhirsch A, Wood WC, Gelber RD, Coates AS, Thurlimann B, Senn HJ. 
Meeting highlights: updated international expert consensus on the primary 
therapy of early breast cancer.  J Clin Oncol  2003 ; 21 : 3357 – 65. 
 Fig. 6.  Design of MINDACT, which aims to spare 10% – 15% of women with node-
negative early-stage breast cancer adjuvant chemotherapy without compromising 
long-term disease outcome. Randomization will be between gene signature and 
Adjuvant! for adjuvant chemotherapy prescription for those cases discordant for 
risk classifi cation by the two methods. 
Evaluate clinico-pathological risk (Adjuvant!) AND 70-gene signature risk
Clinical pathological
AND 70-gene signature
HIGH risk
Clinical pathological
AND 70-gene signature
LOW risk
All horomone
responsive patients
receive endocrine
therapy
Clin-Path HIGH risk
70-gene LOW risk
Clin-Path LOW risk
70-gene HIGH risk
Discordant cases
Use 70-gene risk to decide on
adjuvant chemotherapy or not
Use Clin-Path risk to decide on
adjuvant chemotherapy or not
No
chemotherapy
Chemotherapy
R
1192 ARTICLES Journal of the National Cancer Institute, Vol. 98, No. 17, September 6, 2006
 (10)  Eifel P, Axelson JA, Costa J, Crowley J, Curran WJ Jr, Deshler A, et al. 
 National Institutes of Health Consensus Development Conference State-
ment: adjuvant therapy for breast cancer, November 1 – 3, 2000.  J Natl 
Cancer Inst  2001 ; 93 : 979 – 89. 
 (11)  Simon R, Radmacher MD, Dobbin K, McShane LM. Pitfalls in the use of 
DNA microarray data for diagnostic and prognostic classifi cation.  J Natl 
Cancer Inst  2003 ; 95 : 14 – 8. 
 (12)  Ransohoff DF. Rules of evidence for cancer molecular-marker discovery 
and validation.  Nat Rev Cancer  2004 ; 4 : 309 – 14. 
 (13)  Michiels S, Koscielny S, Hill C. Prediction of cancer outcome with micro-
arrays: a multiple random validation strategy.  Lancet  2005 ; 365 : 488 – 92. 
 (14)  Eden P, Ritz C, Rose C, Ferno M, Peterson C.  “ Good Old ” clinical markers 
have similar power in breast cancer prognosis as microarray gene expres-
sion profi lers.  Eur J Cancer  2004 ; 40 : 1837 – 41. 
 (15)  Todd JH, Dowle C, Williams MR, Elston CW, Ellis IO, Hinton CP, et al. 
Confi rmation of a prognostic index in primary breast cancer.  Br J Cancer 
 1987 ; 56 : 489 – 92. 
 (16)  Ravdin PM, Siminoff LA, Davis GJ, Mercer MB, Hewlett J, Gerson N, et al. 
Computer program to assist in making decisions about adjuvant therapy for 
women with early breast cancer.  J Clin Oncol  2001 ; 19 : 980 – 91. 
 (17)  Singletary SE, Allred C, Ashley P, Bassett LW, Berry D, Bland KI, et al. 
Revision of the American Joint Committee on Cancer staging system for 
breast cancer.  J Clin Oncol  2002 ; 20 : 3628 – 36. 
 (18)  Cardoso F. Microarray technology and its effect on breast cancer 
(re)classifi cation and prediction of outcome.  Breast Cancer Res  2003 ; 5 : 
303 – 4. 
 (19)  Harvey JM, Clark GM, Osborne CK, Allred DC. Estrogen receptor status by 
immunohistochemistry is superior to the ligand-binding assay for predict-
ing response to adjuvant endocrine therapy in breast cancer.  J Clin Oncol 
 1999 ; 17 : 1474 – 81. 
 (20)  Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The 
value of histological grade in breast cancer: experience from a large study 
with long-term follow-up.  Histopathology  1991 ; 19 : 403 – 10. 
 (21)  Olivotto IA, Bajdik CD, Ravdin PM, Speers CH, Coldman AJ, Norris BD, 
et al. Population-based validation of the prognostic model ADJUVANT! for 
early breast cancer.  J Clin Oncol  2005 ; 23 : 2716 – 25. 
 (22)  Effects of chemotherapy and hormonal therapy for early breast cancer on re-
currence and 15-year survival: an overview of the randomised trials.  Lancet 
 2005 ; 365 : 1687 – 717. 
 (23)  Heagerty PJ, Lumley T, Pepe MS. Time-dependent ROC curves for cen-
sored survival data and a diagnostic marker.  Biometrics  2000 ; 56 : 337 – 44. 
 (24)  Kattan MW. Judging new markers by their ability to improve predictive 
accuracy.  J Natl Cancer Inst  2003 ; 95 : 634 – 5. 
 (25)  Simon R. Roadmap for developing and validating therapeutically relevant 
genomic classifi ers.  J Clin Oncol  2005 ; 23 : 7332 – 41. 
 (26)  Jenssen TK, Hovig E. Gene-expression profi ling in breast cancer.  Lancet 
 2005 ; 365 : 634 – 5. 
 (27)  Foekens JA, Atkins D, Zhang Y, Sweep FC, Harbeck N, Paradiso A, et al. 
Multicenter validation of a gene expression-based prognostic signature in 
lymph node-negative primary breast cancer.  J Clin Oncol  2006 ; 24 : 1665 – 71. 
 (28)  Ein-Dor L, Kela I, Getz G, Givol D, Domany E. Outcome signature genes in 
breast cancer: is there a unique set?  Bioinformatics  2004 ; 21 : 171 – 8. 
 (29)  Bogaerts J, Cardoso F, Buyse M, Braga S, Loi S, Harrison J, et al. Prospec-
tive evaluation of a gene signature as a new prognostic tool in early-stage 
breast cancer. Nat Clin Pract Oncol. In press 2006. 
 NOTES 
 This work was partially supported by the European Commission Framework 
Programme VI (FP6-LSHC-CT-2004-503426), the Breast Cancer Research 
Foundation, the  “ Association le Cancer du Sein-Parlons-en, ” and the J. Seroussi 
Foundation. The work of M. Delorenzi was also supported by the National Center 
of Competence in Research Molecular Oncology, a research program of the Swiss 
National Science Foundation. 
 All authors contributed to the manuscript. They are grateful to the many 
 individuals who have made this work possible: N. Decker and C. Straehle (BIG/
TRANSBIG Secretariat, Institut Jules Bordet, Brussels, Belgium) for project co-
ordination; T. Bruinsma, R. Van Laar (Agendia B.V. Amsterdam, The  Netherlands), 
V. Lazar (Institut Gustave Roussy, Villejuif, France), J. Smeds (Karolinska 
 Institute, Stockholm, Sweden), A. Tutt, C. Gillet, K. Ryder (Guy’s Hospital, 
 London, U.K.), and M. Taylor (John Radcliffe Hospital, Oxford, U.K.) for data 
collection and tumor sample management; G. Decoster and J. Schlusselberg 
(IT & GCP Consulting) for clinical site audits; and P. Ravdin (University of 
Texas Health Science Center, San Antonio, TX) for helpful advice and use of 
the  Adjuvant! software. 
 M. Buyse and S. Loi are co-fi rst authors; M. J. Piccart and F. Cardoso are 
co-last authors. 
 L. van’t Veer is a named inventor on a patent application for the 70-gene sig-
nature used in this study. L. van’t Veer, A. M. Glas, and A. Floore are shareholders 
in and are employed by Agendia, the commercial entity that markets the 70-gene 
signature as Mammaprint. There are no other confl icts of interest. The fi rst  authors 
had full access to all the data in the study and take fi nal responsibility for the deci-
sion to submit the study for publication. Apart from providing the Mammaprint 
chips, Agendia had no role in the design, conduct, analysis, or writing of the 
study. 
 Funding to pay the Open Access publication charges for this article was 
 provided by the European Commission Framework Programme VI (FP6- LSHC-
CT-2004-503426). 
 Manuscript received November 12, 2005 ; revised April 27, 2006 ; accepted 
July 14, 2006. 
